This site is intended for healthcare professionals

UK NICE recommends use of Vimizim in mucopolysaccharidosis type 4A.

Read time: 1 mins
Published:23rd Mar 2022

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Vimizim (elosulfase alfa), from BioMarin, for routine use in the NHS, treating mucopolysaccharidosis type 4A (MPS 4A) – a rare metabolic condition that primarily affects the skeleton.

This is the first disease modifying treatment recommended by NICE for routine NHS use.

MPS 4A (also known as Morquio A syndrome) is an autosomal recessive genetic condition which causes growth delays, a prominent lower face, hip dislocation and arthritis, concern for a spine abnormality and an abnormally short neck.

Condition: MPS IV A
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.